Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Osaka Soda Co., Ltd. (4046.T)
Osaka, JP
Established in Osaka, Japan, in 1915, Osaka Soda Co., Ltd. operates as a comprehensive manufacturer and supplier of a diverse range of specialized chemical products. The company's extensive portfolio encompasses fundamental inorganic chemicals, including caustic soda, hydrochloric acid, and various chlorine derivatives such as liquid chlorine, sodium hypochlorite, and chlorine gas, alongside caustic potash and hydrogen. It also produces essential organic chemical intermediates like epichlorohydrin and allyl chloride, as well as key ingredients for paints and adhesives. Advanced polymer offerings include epichlorohydrin and acrylic rubbers, in addition to diallyl phthalate, non-phthalate allyl, and epoxy resins. A significant area of expertise lies in high-performance silica gels, vital for the analysis and purification processes in pharmaceuticals, cosmetics, and functional foods. Furthermore, Osaka Soda develops active pharmaceutical ingredients (APIs) and their precursors, polysulfide silane coupling agents, components for electrodes and lenses, and sophisticated materials for pharmaceutical purification. Their product lineup also features analytical instrumentation, packed columns, chiral compounds, photosensitive resins, color resists, and glass fibers. Beyond its chemical manufacturing core, the company provides decorative boards, items for housing facilities, and health-related consumables. Osaka Soda also delivers crucial services, including the transportation and storage of chemical products, the engineering of chemical plants and environmental preservation systems, and comprehensive material recycling for fluorescent and mercury lamps, glass, and metals. The firm adopted its current name, Osaka Soda Co., Ltd., in October 2015, having previously been known as DAISO Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.50% | +2.18% | +2.07% | -17.79% | +0.16% | -14.23% | +31.28% | +145.15% | +289.23% | +378.11% | +961.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+3.7% Q1'26: +20.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+52.0% ★ Q1'26: +106.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+12.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+17.6% ★ Q1'26: +17.9% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+14.7% ★ Q1'26: +16.6% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-1.6% ★ Q1'26: -2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.35× ★ Q1'26: 0.33× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 5 EPS Ana. |
Mar 2027 4 Rev. Ana. 4 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
101.37B
est: 94.50B (+7.3%)
|
102.13B
est: 105.00B (-2.7%)
|
93.51B
est: 99.00B (-5.5%)
|
101.23B
est: 101.00B (+0.2%)
|
107.87B
est: 110.00B (-1.9%)
|
105.48B
est: 108.00B (-2.3%)
|
97.27B
est: 97.00B (+0.3%)
|
88.08B
est: 85.46B (+3.1%)
|
104.21B
est: 101.50B (+2.7%)
|
94.56B
est: 95.48B (-1.0%)
|
96.43B
est: 100.78B (-4.3%)
|
101.49B
99.76B – 103.06B
+0.7% YoY
|
108.55B
102.68B – 111.41B
+7.0% YoY
|
118.23B
112.51B – 121.88B
+8.9% YoY
|
| EBITDA |
8.12B
est: 16.25B (-50.1%)
|
9.46B
est: 18.06B (-47.6%)
|
9.66B
est: 17.02B (-43.2%)
|
10.67B
est: 17.37B (-38.6%)
|
13.27B
est: 18.92B (-29.9%)
|
13.51B
est: 18.57B (-27.3%)
|
12.42B
est: 16.68B (-25.6%)
|
16.32B
est: 14.70B (+11.0%)
|
19.04B
est: 17.45B (+9.1%)
|
14.25B
est: 21.15B (-32.6%)
|
17.78B
est: 22.32B (-20.3%)
|
22.48B
22.09B – 22.83B
+0.7% YoY
|
24.04B
22.74B – 24.68B
+7.0% YoY
|
26.19B
24.92B – 26.99B
+8.9% YoY
|
| EBIT |
5.17B
est: 12.44B (-58.4%)
|
6.44B
est: 13.82B (-53.4%)
|
6.59B
est: 13.03B (-49.5%)
|
7.32B
est: 13.30B (-44.9%)
|
9.49B
est: 14.48B (-34.5%)
|
9.70B
est: 14.22B (-31.8%)
|
8.34B
est: 12.77B (-34.7%)
|
12.40B
est: 11.25B (+10.3%)
|
15.31B
est: 13.36B (+14.6%)
|
10.51B
est: 17.52B (-40.0%)
|
13.82B
est: 18.49B (-25.3%)
|
18.62B
18.31B – 18.91B
+0.7% YoY
|
19.92B
18.84B – 20.44B
+7.0% YoY
|
21.70B
20.65B – 22.37B
+8.9% YoY
|
| Net Income |
3.45B
est: 3.85B (-10.4%)
|
3.61B
est: 4.42B (-18.5%)
|
4.32B
est: 5.17B (-16.4%)
|
4.78B
est: 5.05B (-5.3%)
|
6.79B
est: 6.23B (+9.1%)
|
6.51B
est: 6.64B (-2.0%)
|
6.05B
est: 5.45B (+11.0%)
|
9.44B
est: 9.51B (-0.7%)
|
10.57B
est: 12.23B (-13.6%)
|
7.65B
est: 8.03B (-4.8%)
|
10.33B
est: 10.59B (-2.5%)
|
13.62B
12.99B – 14.26B
+28.6% YoY
|
14.62B
14.39B – 16.26B
+7.3% YoY
|
17.46B
16.36B – 19.50B
+19.4% YoY
|
| SGA |
8.85B
est: 11.12B (-20.4%)
|
9.60B
est: 12.35B (-22.3%)
|
9.62B
est: 11.64B (-17.4%)
|
10.27B
est: 11.88B (-13.6%)
|
10.91B
est: 12.94B (-15.7%)
|
10.28B
est: 12.70B (-19.1%)
|
10.07B
est: 11.41B (-11.7%)
|
11.16B
est: 10.05B (+11.0%)
|
12.02B
est: 11.94B (+0.7%)
|
11.19B
est: 11.23B (-0.4%)
|
11.97B
est: 11.85B (+1.0%)
|
11.94B
11.73B – 12.12B
+0.7% YoY
|
12.77B
12.08B – 13.10B
+7.0% YoY
|
13.91B
13.23B – 14.34B
+8.9% YoY
|
| EPS |
32.75
est: 30.40 (+7.7%)
|
34.23
est: 34.90 (-1.9%)
|
41.01
est: 40.80 (+0.5%)
|
44.64
est: 39.82 (+12.1%)
|
59.42
est: 49.16 (+20.9%)
|
55.22
est: 52.38 (+5.4%)
|
51.47
est: 43.02 (+19.6%)
|
80.95
est: 75.07 (+7.8%)
|
85.68
est: 97.23 (-11.9%)
|
60.17
est: 63.20 (-4.8%)
|
81.54
est: 87.40 (-6.7%)
|
108.38
102.50 – 112.54
+24.0% YoY
|
121.98
113.56 – 128.33
+12.5% YoY
|
143.80
129.08 – 153.92
+17.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Rayliant SMDAM Japan Equity ETF RAYJ | 2.03% | 509.6K | 0.72% |
| 2 | MUFG Japan Small Cap Active ETF MJSC | 0.91% | 208.7K | 0.85% |
| 3 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.08% | 317.3K | 0.58% |
| 4 | State Street SPDR S&P International Small Cap ETF GWX | 0.08% | 702.5K | 0.40% |
| 5 | iShares MSCI Japan Small-Cap ETF SCJ | 0.06% | 161.1K | 0.50% |
| 6 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.06% | 334.0K | 0.58% |
| 7 | Schwab International Small-Cap Equity ETF SCHC | 0.04% | 2.14M | 0.06% |
| 8 | Schwab Fundamental International Small Company Index ETF FNDC | 0.03% | 858.0K | 0.39% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 3.87M | 0.06% |
| 10 | WisdomTree International Equity Fund DWM | 0.02% | 163.9K | 0.48% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsuo Konishi | Lead Executive Officer, GM of Engineering & Technology Division and Director | — | male |
| Eiji Masuda | President & CEO of Daiso Chemical Co., Ltd. | — | male |
| Kenshi Terada | Representative Chairman, President & CEO | — | male |
| Masayuki Kawakami | Executive Officer & GM of Human Resources DEPT. and Secretariat | — | — |
| Takeshi Kimura | Director & Lead Executive Officer | — | male |
| Toru Imamura | Executive Officer & GM of Administration Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4046.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
